A vaccine of recombinant canarypox virus
expressing feline interleukin-2 (IL-2) is approved for use in Europe as adjunctive immunotherapy after surgery for some feline cancers, including feline injection-site sarcomas, or fibrosarcomas.
However, 4 samples (18%) had antibody to canarypox virus
antigen with test sample and negative control ratios (P/N values) ranging from 2.4 to 6.5 (median 4.3).
Live canarypox virus
that expresses the rabies virus glycoprotein has been licensed in the USA as a parenteral monovalent vaccine for cats and as a combination rabies vaccines for cats with feline panleukopenia virus, feline parvovirus, feline calicivirus vaccines included in the product (51).
Both strains were found in all 3 passerine taxa, and sequences from both strains were less than 5% different from each other and from canarypox virus
. In contrast, chickens in Galapagos were infected with a virus that appears to be identical in sequence to the characterized fowlpox virus and about 30% different from the canarypox/Galapagos group viruses in the regions sequenced.
Two vaccines are available for vaccinating equines: an inactivated WNV vaccine and a recombinant vaccine that uses canarypox virus
to express WNV antigens (44,45).